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Summary The aim of the study was to investigate serum 25-hy-
droxyvitamin D (25(OH) D3) levels in patients with vitiligo vulgaris in 
terms of causal relation and extension of the disorder.
This study is a clinical cross-sectional study carried out in order to de-
termine 25-hydroxyvitamin D levels among 25 patients with vitiligo 
vulgaris and in 41 controls. Fitzpatrick skin phototypes, history of auto-
immune disease, family history of vitiligo, and duration of the disease 
were also evaluated.
The mean levels of vitamin D in patient and the control group were 
15.2±5.2 ng/dL and 14.4±6.2 ng/dL respectively (P>0.05). In our study, 
48% of the patients had insufficient (<30 ng/mL) and 52% had very low 
(<15 ng/mL) levels of vitamin D. There was no correlation between age, 
duration of the disease, and body surface area affected with vitamin D 
levels. There was no significant difference in vitamin D levels between 
patients who had family history of vitiligo (5 patients, 20%) and those 
that did not. 
Vitamin D levels were found to be insufficient (<30 ng/mL) or very low 
(<15 ng/mL) in most of the patients with vitiligo vulgaris, but not statis-
tically significantly different as a group when compared to the controls. 
More studies are needed to differentiate between the effects of low vi-
tamin D levels on pathogenesis of vitiligo vulgaris and lower vitamin D 
levels as a result of the disease.
Key worDS: vitamin D, vitiligo, autoimmunity, hypopigmentation 
IntroDuCtIon
Vitiligo is an acquired disorder characterized 
by depigmentation of skin that affects 1-2% of the 
population worldwide (1). It is the most common dis-
order that is equally likely in both genders and can 
occur at any age. Although the real cause of vitiligo 
is unknown, the autoimmune theory is the one that 
is best supported. Vitiligo can occur along with other 
autoimmune diseases including pernicious anemia, 
hyperthyroidism, Hashimoto’s thyroiditis, alopecia 
areata, and adrenocortical failure (2,3). The disease 
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Age (yr; mean ± SD) 33.9 ± 19.4
Sex
Male, n 13
Female, n 12 
Duration of disease (yr)
mean ± SD 5.36 ± 6.41




Fitzpatrick skin type 
II, n 6
III, n 19
is inherited multifactorially, with a polygenic pattern 
and incomplete penetrance (1). 
Histological studies have shown the absence of 
melanocytes in the affected skin (4). Evidence sup-
ports that both humoral and cellular immunity play 
a role in vitiligo (5-7). The importance of the T regu-
latory CD4+ cell subset (Treg) in the pathogenesis of 
many autoimmune diseases is already known. At the 
site of depigmentation, T cell infiltrates are invariably 
seen in patients with active vitiligo, along with a high 
frequency of cytotoxic T lymphocytes specific for me-
lanocytic antigens, suggesting a direct melanocyte 
specific T cell attack (8).
Vitamin D deficiency is a global health problem. 
Although the effects of vitamin D on bone and min-
eral metabolism are well established, its implications 
on the immune system are still under investigation. 
Vitamin D receptors have been found in all immune-
system cells, including activated CD4+ and CD8+ T 
cells, B cells, neutrophils, and antigen presenting cells 
(macrophage and dendritic cells) (9). The associa-
tion between vitamin D and autoimmune diseases, 
such as type 1 diabetes mellitus, multiple sclerosis, 
rheumatoid arthritis, systemic lupus erythematosus, 
asthma, and inflammatory bowel disease, has been 
established (10). Whether this association indicates a 
causal relation is a matter of debate. 
Currently, topical vitamin D3 analogues such as 
calcipotriene are used to treat vitiligo, but the blood 
levels of vitamin D in patients with vitiligo are not 
clinically well established. 
In this study our aim was to investigate the serum 
25(OH) D3 levels in patients with vitiligo vulgaris (VV) 
in terms of causal relation and extension of the dis-
order.
PatIentS anD methoDS
The present study is a clinical cross-sectional study 
carried out among the patients with VV in the Depart-
ment of Dermatology at the Mustafa Kemal Univer-
sity Hospital between 2010 and 2011. The study was 
approved by the local Ethical Committee of the Mus-
tafa Kemal University (Hatay, Turkey). The study was 
conducted in accordance with the Declaration of Hel-
sinki. Informed consent of the all participants was ob-
tained. The VV is diagnosed by an investigator (G.S). 
Patients taking oral vitamin D supplements or topical 
vitamin D, with a history of phototherapy in the last 
year, history of systemic disease, or with the presence 
of chronic inflammatory disease and incomplete doc-
umentation were excluded from the study. 
During the interview in the clinic, Fitzpatrick skin 
phototypes, history of autoimmune disease, family 
history of vitiligo, and duration of the disease were 
recorded for patients included in the study.
Twenty five of patients with VV and 41 from con-
trol group had sera drawn to determine 25(OH)-D3 
levels. To avoid seasonal variations, blood samples 
from the control group were taken at the same time 
as the patient group. All the subjects were from the 
metropolitan area of Hatay, in order to avoid geo-
graphic differences in sun exposure and vitamin D 
levels. Laboratory testing was performed in the bio-
chemistry laboratory of Mustafa Kemal University, 
Turkey. Blood samples were drawn from the ante-
cubital vein by careful vein puncture in a 21 G ster-
ile syringe without stasis at 08.00–10.00 AM after a 
fasting period of 12 h and then centrifuged at 4000 g 
for 5 min to separate plasma for 25(OH)-D. The blood 
samples were also analyzed for data on complete 
blood counts, creatinine, alanine aminotransferase, 
aspartate aminotransferase, and thyroid-stimulating 
hormone (TSH).
Serum 25-hydroxyvitamin D levels were deter-
mined via chemiluminescence by ARCHITECT i2000 
system. Vitamin D deficiency is defined as a 25(OH)D3 
level below 20 ng/mL, very low levels as 15 ng/mL, 
insufficiency as 21–29 ng/mL, and sufficiency as a 
25(OH)D3 level of 30–100 ng/mL (11,12).
StatIStICaL anaLySIS
Statistical analysis was performed with the SPSS 
software version 15. The variables were investigated 
using visual and analytical methods (Kolmogorov-
Siminov/Shapiro-Wilk test) to find out whether or 
not they are normally distributed. Descriptive analyis 
was presented using medians for the non-normally 
table 1. Characteristics of the vitiligo group (yr: 
years; n: numbers; SD: standard deviation; BSA: 
Body surface area) 
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distributed variables. The Mann-Whitney U test was 
used to compare ages and vitamin D levels between 
the patient and control groups. P-value of less than 
0.05 was considered statistically significant.
reSuLtS
A total of 25 patients and 41 controls were includ-
ed in the study. The patient population consisted of 
13 men and 12 women, with an overall mean (± stan-
dard deviation) age of 33.9 ± 19.4 years. The control 
group consisted of 20 men and 21 women, with an 
overall mean age of 34.7 ± 15.9. There was no signifi-
cant difference in mean age between the patient and 
the control group (P>0.05). The mean levels of vita-
min D in the patient and control group were 15.2 ± 
5.2 ng/dL and 14.4 ± 6.2 ng/dL respectively (P>0.05). 
Twenty patients and 34 control group had vitamin D 
deficiency. Four patients had a family history of viti-
ligo. Only one patient had a history of another auto-
immune disease: Graves disease. There was no corre-
lation between the vitamin D levels and percentage 
of the affected body surface area (P>0.05, r = 0.002). 
There was also no correlation between vitamin D lev-
els and duration of the vitiligo (P>0.05, r = 0.209).
Six patients had Fitzpatrick skin phototype 2 
while the 19 had phototype 3. Control and the pa-
tient groups did not significantly differ in Fitzpatrick 
skin phototype.
DISCuSSIon
Our study investigated vitamin 25(OH)D3 levels 
of patients with VV. A case control study in a Chinese 
population showed no correlation between vitamin d 
levels and onset of vitiligo (13). In a case control study 
from Egypt, Saleh et al. found 25(OH)D3 deficiency 
in vitiligo patients with and without autoimmune 
diseases (14). Another study by Silverberg et al. has 
limitations because there was no control group, but is 
worth considering (12). In our study, there was no dif-
ference between the patients and the control group 
with respect to 25(OH) D3 levels. In Silverberg et al., 
55.6% of the subjects had insufficient (<30 ng/mL) 
and 13.3% had very low (<15 ng/mL) vitamin D levels 
(12). In comparison, in our study 48% had insufficient 
(<30 ng/mL) and 52% of the patients had very low 
(<15 ng/mL) levels of vitamin D. None of the patients 
had sufficient (>30 ng/mL) levels. On the other hand, 
in the control group 31.7% had insufficient, 65.9% 
had very low, and only one participant had sufficient 
vitamin D levels (Figure 1). None of the subjects in 
control group had severe deficiency. In our study, the 
low levels of vitamin D may be related to the time the 
blood samples were collected, since all of the patients 
participated in the study during winter and autumn.
Regarding the Fitzpatrick skin phototype, there 
was no statistical difference in vitamin D levels be-
tween the skin type II and III. Silverberg et al. found a 
correlation between vitamin D insufficiency and Fitz-
patrick skin phototype, but the correlation did not 
exist with very low levels when using the 15 ng/mL 
cut-off point. There are some studies that show cor-
relation between age and vitamin D, whereas others 
found no correlation (15-17). In our study, there was 
no correlation between age and vitamin D levels. 
Silverberg et al. found that patients with comorbid 
autoimmunity were more likely to have very low vita-
min D levels (12). We had only one patient who had 
Graves’ disease, with a vitamin D level of 19 ng/mL 
which is considered to be deficient but not very low 
(<15 ng/mL). There is a study by Yamashita et al that 
shows increased prevalence of vitamin D deficiency 
in Graves’ disease (18).
There was no significant difference with respect 
to vitamin D levels between patients who had family 
history of vitiligo (n = 5, 20%) and those that did not. 
There was also no correlation between the vitamin D 
and duration of the disease and body surface area af-
fected. Six (24%) of the patients had relapsing VV, but 
there was to significant difference in vitamin D levels 
compared with the non relapsing group. 
 Vitamin D receptors play a central role in the 
biological actions of vitamin D, and these receptors 
are found in almost all immune-system cells includ-
ing T cells, B cells, neutrophils, and antigen present-
ing cells (9,19). There is large number of studies that 
implicates that 1.25 (OH)2D3 influences the immune 
Figure 1. Vitamin D levels of the patient and the con-
trol groups.
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system, but whether this relation is a cause or result 
of the autoimmune diseases is not clear. Vitamin D 
levels can vary significantly in populations due to 
geographical, economic, and social factors. The levels 
that may cause bone disease (<8 ng/mL) or elevate 
parathyroid hormone levels (<30 ng/mL) have been 
established, but the levels that triggers autoimmune 
diseases should be studied (20). 
ConCLuSIon 
More studies are needed to establish the effect of 
low vitamin D levels as part of the pathogenesis of 
immune diseases rather than a result of the diseases. 
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